ZG Form 4: Hofmann Exercises Options and Executes 10b5-1 Sale
Rhea-AI Filing Summary
Jeremy Hofmann, Chief Financial Officer of Zillow Group, executed transactions on 09/08/2025. He exercised a fully vested option to acquire 25,000 shares of Class C capital stock at an exercise price of $38.78 per share. The exercise increased the amount of Class C shares associated with the option position and is reported in Table II as 25,000 underlying shares.
On the same date, Hofmann sold 25,000 shares of Class C capital stock pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2024. The weighted-average sale price was $89.9936 per share, with individual sale prices ranging from $89.98 to $90.0450. After these transactions the reporting person held 84,146 shares of Class C capital stock beneficially. The Form 4 was signed by Attorney-in-Fact Shannon Cartales on 09/10/2025.
Positive
- Exercise of fully vested options to acquire 25,000 shares at $38.78 shows planned option monetization rather than ad hoc selling.
- Sale executed under a Rule 10b5-1 trading plan adopted Sept 4, 2024, indicating pre-established compliance procedures for insider trades.
Negative
- Insider sale of 25,000 shares on 09/08/2025 reduced beneficial ownership to 84,146 shares, representing realized insider liquidity.
Insights
TL;DR: CFO exercised vested options and sold an equal number of shares under a 10b5-1 plan; transactions appear routine and preplanned.
The report shows a simultaneous option exercise for 25,000 shares at $38.78 and a sale of 25,000 Class C shares at a weighted-average price of $89.9936 executed under a Rule 10b5-1 plan. The exercise was of fully vested options, and the sale was effected pursuant to a pre-established trading plan adopted Sept 4, 2024, reducing the reporting person’s beneficial holdings to 84,146 shares. For investors, these transactions document routine insider liquidity and option monetization rather than an ad hoc market signal.
TL;DR: Transactions comply with Rule 10b5-1 framework; timing and disclosure indicate adherence to insider-trading controls.
The filing discloses an option exercise and contemporaneous sales executed under a Rule 10b5-1 plan, with the filer providing the required explanation of the plan. The presence of a signed Form 4 and explicit disclosure of the plan adoption date and weighted-average sale price supports transparent compliance. There is no disclosure in this Form 4 of any amendment or irregularity; therefore, from a governance perspective these are routine, properly disclosed insider transactions.